Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.46 |
| ▸ | NT5E | P21589 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 4/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 3/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3964706 | 0.82 | CDK1 (0.57) | AHCYADORA2AADORA1ADORA2BCDK1 | |
| SCHEMBL130527 | 0.79 | CDK1 (0.64) | AHCYNT5ELMNAHIF1AADORA2A | |
| SCHEMBL7624342 | 0.78 | AHCY (0.50) | AHCYNT5ELMNAHIF1AADORA2A | |
| SCHEMBL17040219 | 0.77 | AHCY (0.49) | AHCYNT5ELMNAHIF1AADORA2A | |
| SCHEMBL21451434 | 0.75 | CDK1 (0.71) | AHCYNT5ELMNAHIF1AADORA2A | |
| SCHEMBL14039518 | 0.75 | CDK1 (0.71) | AHCYNT5ELMNAHIF1AADORA2A | |
| SCHEMBL13389895 | 0.75 | PI4KA (0.58) | AHCYNT5ELMNAHIF1AADORA2A | |
| SCHEMBL24434420 | 0.74 | AHCY (0.47) | AHCYNT5ELMNAHIF1AADORA2A | |
| SCHEMBL21504426 | 0.73 | CDK1 (0.55) | AHCYNT5ELMNAHIF1AADORA2A | |
| SCHEMBL6883849 | 0.73 | ADORA2A (0.61) | AHCYADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5965591-A | MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | claimed |
| US-5917040-A | 2-fluoro-9-trimethylsilyladenine | ASH STEVENS, INC. (US) | 1999-06-29 | — | — | US | claimed |
| EP-0578208-B1 | Process for the preparation of 2-fluoro-9-(2,3,5-tri-O-benzyl-beta-arabinofuranozyl)adenine | ASH STEVENS INC (US) | 1995-12-27 | — | — | EP | claimed |
| EP-0578208-A1 | Process for the preparation of 2-fluoro-9-(2,3,5-tri-O-benzyl-beta-arabinofuranozyl)adenine | ASH STEVENS, INC. (US) | 1994-01-12 | — | — | EP | claimed |
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | UTI LIMITED PARTNERSHIP (CA) | 2018-02-08 | — | — | US | disclosed |
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | UTI LIMITED PARTNERSHIP (CA) | 2018-02-08 | — | — | US | disclosed |
| US-5917040-A | 2-fluoro-9-trimethylsilyladenine | ASH STEVENS, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| US-5917040-A | 2-fluoro-9-trimethylsilyladenine | ASH STEVENS, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0578208-B1 | Process for the preparation of 2-fluoro-9-(2,3,5-tri-O-benzyl-beta-arabinofuranozyl)adenine | ASH STEVENS INC (US) | 1995-12-27 | — | — | EP | disclosed |
| EP-0578208-A1 | Process for the preparation of 2-fluoro-9-(2,3,5-tri-O-benzyl-beta-arabinofuranozyl)adenine | ASH STEVENS, INC. (US) | 1994-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | PNP, NUDT1, SLC29A1 | AHCY 1682/4885NT5E 22/4885LMNA 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.